Development of a novel BRCAness score that predicts response to PARP inhibitors

BACKGROUND: BRCAness is a characteristic feature of homologous recombination deficiency (HRD) mimicking BRCA gene mutation in breast cancer. We hypothesized that a measure to quantify BRCAness that causes synthetic lethality in BRCA mutated tumors will identify responders to PARP inhibitors. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshi, Masanori, Gandhi, Shipra, Wu, Rongrong, Asaoka, Mariko, Yan, Li, Yamada, Akimitsu, Yamamoto, Shinya, Narui, Kazutaka, Chishima, Takashi, Ishikawa, Takashi, Endo, Itaru, Takabe, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652967/
https://www.ncbi.nlm.nih.gov/pubmed/36371386
http://dx.doi.org/10.1186/s40364-022-00427-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652967/
https://www.ncbi.nlm.nih.gov/pubmed/36371386
http://dx.doi.org/10.1186/s40364-022-00427-8

Ejemplares similares